Literature DB >> 31094778

Attenuation of Unevoked Mechanical and Cold Pain Hypersensitivities Associated With Experimental Neuropathy in Mice by Angiotensin II Type-2 Receptor Antagonism.

Andrew J Shepherd1, Durga P Mohapatra.   

Abstract

Recent findings from a phase II clinical trial showed analgesic effects of an angiotensin II type-2 receptor (AT2R) antagonist in postherpetic neuralgia patients. This study aimed to investigate whether AT2R antagonism could provide effective analgesia in voluntary measures of unevoked/ongoing pain-like behaviors in mice with experimental neuropathy. Mice were subjected to spared nerve injury to induce neuropathy and tested in 2 operant behavioral tests to measure ongoing mechanical and cold pain hypersensitivities. Systemic administration of an AT2R antagonist provided effective analgesia in these behavioral measures of mechanical and cold pain in spared nerve injury mice, suggesting its effectiveness in neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31094778      PMCID: PMC6652216          DOI: 10.1213/ANE.0000000000003857

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  18 in total

1.  EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Authors:  Andrew S C Rice; Robert H Dworkin; Tom D McCarthy; Praveen Anand; Chas Bountra; Philip I McCloud; Julie Hill; Gary Cutter; Geoff Kitson; Nuket Desem; Milton Raff
Journal:  Lancet       Date:  2014-02-05       Impact factor: 79.321

Review 2.  Gabapentin for chronic neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; Rae F Bell; Andrew Sc Rice; Thomas Rudolf Tölle; Tudor Phillips; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-09

3.  A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.

Authors:  Maree T Smith; Trent M Woodruff; Bruce D Wyse; Arjun Muralidharan; Thomas Walther
Journal:  Pain Med       Date:  2013-06-06       Impact factor: 3.750

Review 4.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

Authors:  Maree T Smith; Bruce D Wyse; Stephen R Edwards
Journal:  Pain Med       Date:  2013-03-14       Impact factor: 3.750

6.  Macrophage angiotensin II type 2 receptor triggers neuropathic pain.

Authors:  Andrew J Shepherd; Aaron D Mickle; Judith P Golden; Madison R Mack; Carmen M Halabi; Annette D de Kloet; Vijay K Samineni; Brian S Kim; Eric G Krause; Robert W Gereau; Durga P Mohapatra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-06       Impact factor: 11.205

7.  Mechanical Conflict System: A Novel Operant Method for the Assessment of Nociceptive Behavior.

Authors:  Steven E Harte; Jessica B Meyers; Renee R Donahue; Bradley K Taylor; Thomas J Morrow
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

8.  EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain.

Authors:  Jan M Keppel Hesselink; Michael E Schatman
Journal:  J Pain Res       Date:  2017-02-20       Impact factor: 3.133

9.  Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS.

Authors:  Takahito Miyake; Saki Nakamura; Meng Zhao; Kanako So; Keisuke Inoue; Tomohiro Numata; Nobuaki Takahashi; Hisashi Shirakawa; Yasuo Mori; Takayuki Nakagawa; Shuji Kaneko
Journal:  Nat Commun       Date:  2016-09-15       Impact factor: 14.919

10.  Inflammation and nerve injury minimally affect mouse voluntary behaviors proposed as indicators of pain.

Authors:  Tayler D Sheahan; Edward R Siuda; Michael R Bruchas; Andrew J Shepherd; Durga P Mohapatra; Robert W Gereau; Judith P Golden
Journal:  Neurobiol Pain       Date:  2017-09-08
View more
  5 in total

1.  Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine.

Authors:  Mihály Balogh; Jelena M Janjic; Andrew J Shepherd
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

3.  Baroreceptor Modulation of the Cardiovascular System, Pain, Consciousness, and Cognition.

Authors:  Heberto Suarez-Roca; Negmeldeen Mamoun; Martin I Sigurdson; William Maixner
Journal:  Compr Physiol       Date:  2021-02-12       Impact factor: 9.090

4.  Neuroprotective Effect of Ramipril Is Mediated by AT2 in a Mouse MODEL of Paclitaxel-Induced Peripheral Neuropathy.

Authors:  Hichem Bouchenaki; Amandine Bernard; Flavien Bessaguet; Simon Frachet; Laurence Richard; Franck Sturtz; Laurent Magy; Sylvie Bourthoumieu; Claire Demiot; Aurore Danigo
Journal:  Pharmaceutics       Date:  2022-04-12       Impact factor: 6.525

Review 5.  Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

Authors:  Kufreobong E Inyang; Joseph K Folger; Geoffroy Laumet
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-26       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.